Tolerability and side-effect profile of rhIL-11

ONCOLOGY

Volumn 14, Issue 9 SUPPL. 8, 2000, Pages 41-47

  Smith, H John W ^a  

^a Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 11; RECOMBINANT COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RECOMBINANT PROTEIN;

ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; DYSPNEA; EDEMA; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ARRHYTHMIA; BLOOD PLATELETS; COLONY-STIMULATING FACTORS, RECOMBINANT; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG INTERACTIONS; DYSPNEA; EDEMA; HUMANS; HYPOKALEMIA; INTERLEUKIN-11; PLATELET ACTIVATION; RECOMBINANT PROTEINS; SAFETY; THROMBOCYTOPENIA;

EID: 0034278345     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Tepler I, Elias L, Smith JW 2nd, et al: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607-3614, 1996.
2. Isaacs C, Robert NJ, Bailey FA, et al: Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 15:3368-3377, 1997.
3. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al: A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 87:3615-3624, 1996.
4. Bracho F, Davenport V, Goldman S, et al: Results of a phase I/II trial of interleukin-11 (IL-11) in combination with G-CSF in children with solid tumors following ifosfamide, carboplatin, etoposide (ICE): Maximal tolerated dose (MTD) is 50% of adult dose and is associated with enhanced hematopoietic reconstitution (abstract 207). Proc Am Soc Clin Oncol 19:54a, 2000.
5. Data on file, Genetics Institute, Cambridge, Mass.
6. Smith IIJW, Beach K, Bedrosian CL, et al: Neumega (Oprelvekin; rhIL-11) prevents severe chemotherapy-induced thrombocytopenia in abbreviated phase 3 study (abstract 1555). Blood 92:377a, 1998.
7. Dykstra K, Rogge H, Stone A, et al: Effect of diuretic treatment on rhIL-11-induced salt and water retention (abstract 1371). Blood 88:346a, 1996.
8. Ault K, Mitchell J, Knowles C: Recombinant human interleukin eleven (Neumega rhIL-11 growth factor) increases plasma volume and decreases urine sodium excretion in normal human subjects (abstract). Blood 84:276a, 1994.
9. Kinlay S, Leiten JW, Neil A, et al: Cardiac event recorders yield more diagnoses and are more cost-effective than 48-hour Holler monitoring in patients with palpitations. A controlled clinical trial. Ann Intern Med 124:16-20, 1996.
10. Frank J, O'Grady M, Abrams-Ogg A, et al: The effects of interleukin-II on cardiovascular parameters in the dog. J Vet Intent Med 12:198, 1998.
11. Ravelli F, Allessie M: Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 96:1686-1695, 1997.
12. Kushner I: The phenomenon of the acute phase response. Ann NY Acad Sci 82:39-48, 1982.
13. Vial T, Descotes J: Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Safety 13:371-406, 1995.